U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H20F3N3O4.ClH
Molecular Weight 447.836
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CADROFLOXACIN HYDROCHLORIDE

SMILES

Cl.C[C@H]1CN(CCN1)C2=C(OC(F)F)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O

InChI

InChIKey=AWPMTCKEQGUMTG-FVGYRXGTSA-N
InChI=1S/C19H20F3N3O4.ClH/c1-9-7-24(5-4-23-9)15-13(20)6-11-14(17(15)29-19(21)22)25(10-2-3-10)8-12(16(11)26)18(27)28;/h6,8-10,19,23H,2-5,7H2,1H3,(H,27,28);1H/t9-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H20F3N3O4
Molecular Weight 411.375
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8723467

Cadrofloxacin hydrochloride was studied for the treatment of bacterial infections. The compound was originally developed by UBE and Daiichi Sankyo. However, this study was discontinued. The compound currently was developed by Hengrui. Cadrofloxacin showed potent bactericidal activity against S. aureus, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Staphylococcus aureus growth
Target ID: Streptococcus pneumoniae growth
Target ID: Haemophilus influenzae growth
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Antimicrobial activity of CS-940, a new trifluorinated quinolone.
1995 Oct
[Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media].
1996 Aug
[In vitro anti-MAC activities of new quinolones in focus (1)].
1996 Sep
Patents

Sample Use Guides

400 mg cadrofloxacin hydrochloride once a day for 7 d by intravenous drip infusion
Route of Administration: Intravenous
In Vitro Use Guide
Cadrofloxacin (CS-940) was active against methicillin-resistant S. aureus with MIC90 of 16 ug/ml.
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:49:31 GMT 2023
Edited
by admin
on Sat Dec 16 05:49:31 GMT 2023
Record UNII
2XR10ID7XQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CADROFLOXACIN HYDROCHLORIDE
Common Name English
CS-940
Code English
CADROFLOXACIN HYDROCHLORIDE [JAN]
Common Name English
3-QUINOLINECARBOXYLIC ACID, 1-CYCLOPROPYL-8-(DIFLUOROMETHOXY)-6-FLUORO-1,4-DIHYDRO-7-((3S)-3-METHYL-1-PIPERAZINYL)-4-OXO-, MONOHYDROCHLORIDE
Systematic Name English
CADEROFLOXACIN HYDROCHLORIDE
Common Name English
CS940
Code English
Code System Code Type Description
CAS
128427-55-4
Created by admin on Sat Dec 16 05:49:31 GMT 2023 , Edited by admin on Sat Dec 16 05:49:31 GMT 2023
PRIMARY
PUBCHEM
9889840
Created by admin on Sat Dec 16 05:49:31 GMT 2023 , Edited by admin on Sat Dec 16 05:49:31 GMT 2023
PRIMARY
FDA UNII
2XR10ID7XQ
Created by admin on Sat Dec 16 05:49:31 GMT 2023 , Edited by admin on Sat Dec 16 05:49:31 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY